Granules India

What business is Granules India?

• Pharma Business
• Granules India has presence across entire manufacturing value chain from APIs, PFIs & FDs
• Strong presence in "first line of defence" products such as Paracetamol, Ibuprofen, Meformin

What's exciting about the business?

• Consciously moving from APIs & PFIs to formulations which have a higher margin. Formulations contribution to go up to 65% in the next 5 years & EBITDA margin to 23% from 17%
• All manufacturing facilites are US.FDA approved
• North America & Europe account for 65% of revenues
• Impressive CAGR of 26% & PAT CAGR of 63% 
• Entered high margin CRAMS business in JV with Omnichem
• Acquired Auctus for 102crs, which has USFDA approved plants, it has added 12 APIs that have higher margins that Granules own. Auctus will be used for forward integration
• Granules will file 10 ANDAs over the next 2 years 
• Dated 2nd October 2015- FIIs have increased their holding to 7.25%, which was 2.85% as on June 30 2015. This shows a 154.38% jump in FIIs share holding in the company. For the first half of the current fiscal, the FIIs’ share holding in the company has surged by 79.45%

Numbers

	FY14	FY15	FY16	FY17
GI-Auctus-Omnichem
Revenues	1096	1178
Growth	47%	7%
EBITDA	158	209
EBITDA Margin	14.4%	17.7%
PAT	75	104
AUCTUS
Revenues		115
Growth
EBITDA		-0.4
EBITDA Margin		-0.3%
PAT		-13
Omnichem
Revenues
Growth
EBITDA
EBITDA Margin
PAT